Significant Ownership of YA II PN, Ltd.

Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for YA II PN, Ltd. focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
/s/ David Gonzalez - David Gonzalez, General Counsel
Manager location
Mountainside, NJ

Follow Filing Activity

Follow YA II PN, Ltd. with Pro and return when a new Schedule 13D/G filing changes the record on this page.

Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.

Review Pro alert access Already have an account? Sign in and return here

Significant Ownership of YA II PN, Ltd.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TVA Texas Ventures Acquisition III Corp Class A Ordinary Shares, $0.0001 par value 28% $89,642,000 +$9,842,000 8,425,000 +12% YA II PN, Ltd. 04 Feb 2026
PWM Prestige Wealth Inc. Class A Ordinary Shares, par value $0.000625 per share 10% $23,158,036 34,564,233 YA II PN, Ltd. 10 Oct 2025
APVO Aptevo Therapeutics Inc. Common Stock 10% $1,663,965 357,842 YA II PN, Ltd. 16 Jun 2025
SLNH Soluna Holdings, Inc. Common Stock 10% $858,309 1,059,641 YA II PN, Ltd. 05 Feb 2025
PRFX PRF Technologies Ltd. Ordinary shares, no par value per share 10% $456,354 333,105 YA II PN, Ltd. 18 Jun 2026
MNDR Mobile-health Network Solutions Class A ordinary shares, par value $0.000032 per share 10% $449,490 316,542 YA II PN, Ltd. 31 Mar 2025
PRFX PRF Technologies Ltd. Ordinary shares, no par value per share 10% $43,306 66,625 YA II PN, Ltd. 07 May 2026
INM InMed Pharmaceuticals Inc. Common Shares 10% $14,885 80,372 YA II PN, Ltd. 13 Dec 2024
RDHL RedHill Biopharma Ltd. American Depositary Shares 9.9% $559,595 508,723 YA II PN, Ltd. 19 Dec 2025
RNAZ TransCode Therapeutics, Inc. Common Stock, $0.0001 par value per share 9.9% $35,620 101,772 YA II PN, Ltd. 15 Apr 2026
SCNI Scinai Immunotherapeutics Ltd. American Depository Shares, each representing 4,000 Ordinary Shares, no par value 9.9% 93,274 YA II PN, Ltd. 24 Mar 2025
Optimi Health Corp. Common Stock, with no par value 7.1% 400,000 YA II PN, Ltd. 20 May 2026
New America Acquisition I Corp. Units, each consisting of one share of Class A common stock, par value $0.0001 per share, and one-half of one redeemable warrant 4.9% 1,490,000 YA II PN, Ltd. 04 Dec 2025
ASST Strive, Inc. Class A Common Stock, $0.001 par value per share 3.6% $28,955,457 +$485,924 39,235,037 +1.7% YA II PN, Ltd. 31 Dec 2025
SQNS Sequans Communications American Depository Shares, each representing ten (10) Ordinary Shares, nominal value Euro 0.01 0.72% $1,010,242 -$12,835,922 1,030,859 -93% YA II PN, Ltd. 30 Sep 2025
FACTU FACT II Acquisition Corp. CUSIP 0.5% $1,007,000 -$16,096,000 100,000 -94% YA II PN, Ltd. 26 Nov 2024
VACH Voyager Acquisition Corp. Class A Ordinary Shares 0.2% $512,500 50,000 YA II PN, Ltd. 31 Dec 2024
INDP Indaptus Therapeutics, Inc. Common Stock 0% $0 -$649,021 0 -100% YA II PN, Ltd. 31 Dec 2025
XOS Xos, Inc. Common Stock, par value $0.0001 0% $0 0 YA II PN, Ltd. 31 Dec 2025
HLBZ micromobility.com Inc. Class A Common Stock 0% $0 0 YA II PN, Ltd. 31 Dec 2024
FFIE Faraday Future Intelligent Electric Inc. Class A Common Stock, par value $0.0001 per share 0% 0 YA II PN, Ltd. 31 Dec 2025

Schedules 13D/G Reported by YA II PN, Ltd.:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .